Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 bridging study of a new ETVAX formulation in healthy adults
2021-001541-13Phase 2Completed
- Sponsor
- Scandinavian Biopharma
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ETVAX in traveler's diarrhea (TD) and Enterotoxigenic Escherichia coli diarrhea (2 arms), sponsored by Scandinavian Biopharma. Primary endpoint: Vaccine responder rate based on anti-LTB serum antibodies. Started Jun 2021; status: completed.
02
Drugs
ETVAX
03
Conditions
traveler's diarrhea (TD)Enterotoxigenic Escherichia coli diarrhea
Beyond the preview
Go deeper on 2021-001541-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001541-13.